Navigation Links
Phase 3 trials of two multi-kinase inhibitors against cancer

Sorafenib and stutent multi-kinase inhibitors against cancer is undergoing phase 3 trials// and these two drugs gained more appreciation in this years ASCO (American Society of Clinical Oncology) conference. This drug is gaining interest due to its multiple mechanism of action – known as Multi-kinase inhibitors. These drugs are in trial against different types of cancer and are found to be very effective. This two multi targeted oncology drug candidate is a small molecule named Sorafenib (Bay43-9006) and stutent (SU11248).

Sorafenib is produced by Onyx pharmaceuticals of California collaborating with Bayer pharmaceuticals of Connecticut and Stutent by Pfizer of New York city. Both these drugs are undergoing phase 3 trials.

Results of the study show that Sorafenib in advanced kidney cancer patients taking the drug lived twice as long as that placebo. Gleevec (imatinib) resistant gastrointestinal stromal tumors (GIST) were much less likely to progress in patients taking stutent versus those on placebo.

Both these drug act against tumor and its ability to recruit new blood vessels essential for growth and dissemination via multiple mechanisms. Sorafenib works by inhibiting the RAF/MEK/ERK pathway and, in parallel, impedes angiogenesis by inhibiting vascular endothelial growth factor-2 (VEGF-2) and platelet derived growth factor beta (PDGF- a). Stutent also has dual actions, killing VEGF and PDGF- á and a as well as FLT-3 and C-KIT.

Pfizer is developing more multi-targeted cancer drugs, such as small AG-013736 which has encouraging results in its phase 2 trials in kidney cancer.

Multi-targeted drug has also downsides of having side effects and allow less flexibility. But, so far there was no side effects reported in Sorafenib or stutent.


'"/>




Page: 1

Related medicine news :

1. SARS-Free Taiwan to Mark End Phase of Global Fight
2. Spray on contraceptive clears Phase I trial
3. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
4. Phase II trails of new HIV vaccine to be held in South Africa
5. FDA approves Phase 0 trial which tests experimental drugs on humans
6. Jalgaon: Third Phase Of Culling Operations Begin
7. Phase 1 Drug Trials on Humans to Be Made Public
8. Lupin Gets DCGI Nod For Phase II Clinical Trials On Desoside-P
9. Cadila to Commence Phase I Clinical Trials On ZYH2
10. iGATE Completes Phase I Testing Of Meningitis Vaccine
11. ADHD Treatment -Phase 3 data on Lisdexamfetamine dimesylate Presented
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/2/2016)... ... May 02, 2016 , ... Dr. Rassouli, dentist in ... cognitive decline. According to the research, which was published in the “Journal of the ... decline, and about 5.4 million Americans have Alzheimer’s disease. The study found that dental ...
(Date:5/2/2016)... ... May 02, 2016 , ... Pregnancy Awareness Month offers a great ... , “If you are ready to have a baby, it’s best to ... HealthChequesTM: Journal Babies is your Personal Conception & Pregnancy Organizer, written for women who ...
(Date:5/2/2016)... ... , ... Dr. Jonathan Kulbersh of Carolina Facial Plastics isn’t surprised that Charlotte, NC, the city ... “ 5 US Cities with the Highest Plastic Rates .” The other cities that ... were calculated using a survey by RealSelf and combining that data with the ...
(Date:5/2/2016)... ... May 02, 2016 , ... The debilitating disease of arthritis can bring patients ... most patients must deal with prescription costs to treat arthritis over the course of ... savings at the pharmacy on many common prescriptions. , Arthritis , Although arthritis is ...
(Date:5/2/2016)... ... May 02, 2016 , ... Advanced ... amniotic fluid/“stem cells” and Platelet Rich Plasma (PRP) injections. “These are becoming the ... James Baranski, D.C., of Advanced Spine & Sport Medical. “We are very excited ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... le 27 Avril 2016 ... progressé de +5% sur le trimestre, soutenu par ... consommables  Croissance de +16% des ventes ... Mauna Kea Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : ... laser, annonce aujourd,hui son chiffre d,affaires pour le ...
(Date:4/27/2016)... NORWALK, Conn. , April 27, 2016 /PRNewswire/ ... availability of its digital health technology platform, which ... services and programs into scalable digital products, Zillion ... mobile engagement and empower consumers to take control ... features face-to-face live video conferencing – including one-to-one, ...
(Date:4/27/2016)... , April 27, 2016 ... of the  "Global Anesthesia Disposables Market 2016-2020" ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ,The global anesthesia disposables ... CAGR of 4.03% during the period 2016-2020.  ... major threat to patients, safety. Organizations like ...
Breaking Medicine Technology: